Skip to main content

Original research on how 303 US institutions turn discoveries into real-world health impact

Live webinar

Racing to Cures: The US/China Biomedical Competitiveness Scorecard

The US leads China in scientific quality and commercial depth. China leads in speed, scale, and cost. Here's the full data behind the race.

Group 72

Why download

  • For VPs of Research & Provosts

    • See the full 35-metric scorecard across six domains, and exactly where your institution's translational performance stacks up against a faster-moving global competitor

    • The US holds a 31% scientific influence advantage. Find out how long the data says that lead will last without structural investment

  • For TTO Directors

    • Why China's discovery-to-IND cycles run 50–70% faster, and what that means for how fast US institutions need to move deals from lab to industry

    • The 64:1 translational bottleneck: see whether your institution's infrastructure puts you in the fast lane or the slow one

  • For Presidents & Institutional Leadership

    • What senior industry leaders say is hardest to replicate on each side, and why complacency, not China's progress, is named as the bigger risk

    • Five specific moves the data says the US needs to make now, and what happens by 2031 if it doesn't
"America's scientific leadership and discovery capabilities are our greatest strategic assets. Discovery alone will not secure our leadership — translation will."

Vanessa Almendro Navarro, PhD, MBA, Senior Vice President and Chief Commercialization Officer, City of Hope

Get the Scorecard